98%
921
2 minutes
20
Purpose: To evaluate outcomes of the Boston type I keratoprosthesis (KPro) and associated incidence of glaucoma.
Design: Retrospective cohort study.
Participants: All patients who underwent KPro surgery at 1 institution from 2003 to 2009 with at least 3 months of follow-up.
Methods: Preoperative visual acuity, diagnosis, history of glaucoma, and intraoperative and postoperative parameters were recorded. Statistical analysis was performed to identify factors that may influence increase in intraocular pressure (IOP) and glaucoma development or progression after surgery.
Main Outcome Measures: Best-corrected visual acuity (BCVA), IOP, postoperative medical and surgical treatments for glaucoma, and KPro retention and complications.
Results: Thirty-six KPro procedures were performed in 30 eyes of 29 patients with a mean (±SD) follow-up of 17 ± 19 months (range, 3-67 months). The main indication for KPro implantation was corneal graft failure (77%). Primary KPro procedures were performed in 23% of eyes for limbal stem cell deficiency secondary to chemical burns and aniridia and for herpetic disease. Median preoperative BCVA was hand motions with an overall improvement to 20/330 (range, 20/20 to hand motions) at 9 months postoperatively; mean BCVA was 20/600 (range, 20/40 to NLP) at the last follow-up. Twenty eyes (67%) had a preoperative history of glaucoma, with 8 of those eyes (40%) having undergone previous glaucoma surgery. Twenty-one eyes (70%) underwent concomitant glaucoma surgery. Postoperative increased IOP (22 mm Hg or higher) was noted in 15 eyes (50%), although definite glaucoma development or progression was noted in 7 of those 15 eyes (23% of total eyes). Mean BCVA at the last follow-up in eyes with glaucoma development or progression was 3/200 compared with 20/563 in the remaining 23 eyes. Six patients (20%) required repeat KPro implantation, and retroprosthetic membranes developed in 23 eyes (77%). No patient had vitritis or infectious endophthalmitis develop.
Conclusions: The Boston type I KPro is an effective option for management of eyes with poor prognosis for primary or repeat penetrating keratoplasty. Visual potential is limited by preoperative comorbidities; however, glaucoma development or progression of preexisting glaucoma is a significant cause of postoperative visual loss. Rigorous perioperative management of elevated IOP is essential for long-term success of KPro surgery.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539166 | PMC |
http://dx.doi.org/10.1097/ICO.0b013e31820f7a32 | DOI Listing |
Hum Cell
September 2025
Eye Hospital, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Age-related eye diseases (AREDs) are the leading cause of visual impairment in the elderly, affecting the structure of the anterior and posterior segments of the eye, significantly reducing the quality of life of patients, and even leading to irreversible blindness. Typical AREDs include age-related cataract (ARC), dry eye disease (DED), age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR), the global prevalence of which continues to rise, becoming a serious public health concern. SIRT1 is an NAD + dependent deacetylase, which plays an important physiological regulatory role in ocular tissues, mainly affecting gene expression and various cellular processes by regulating the acetylation status of substrate proteins.
View Article and Find Full Text PDFSurv Ophthalmol
September 2025
Department of Ophthalmology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Weifang 261041, China.
Lipid metabolism plays a critical role in maintaining normal physiological functions and is strongly linked to the pathogenesis of ocular vascular diseases. This review examines how disorders of lipid metabolism drive progression in ocular vascular diseases, including diabetic retinopathy, age-related macular degeneration, retinal vascular occlusive diseases, and retinopathy of prematurity. These disorders are classified as a related group due to their common feature of impaired ocular vascularization.
View Article and Find Full Text PDFBioorg Chem
August 2025
Department of Chemistry, Faculty of Science, Atatürk University, 25240 Erzurum, Türkiye. Electronic address:
Compounds that possess a benzene sulfonamide structure are utilized in a wide range of fields. Benzene bissulfonamides are also important compounds in the field of organic and medicinal chemistry. Based on these features, a series of benzene bissulfonamides were synthesized in moderate yields starting from 3-methylanisole.
View Article and Find Full Text PDFJMIR AI
September 2025
Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Facoltà di Medicina e Chirurgia East Tower-6th Floor Via Montpellier 1, Rome, 00133, Italy, 39 3484772028.
Background: Artificial intelligence (AI) is becoming increasingly popular in the scientific field, as it allows for the analysis of extensive datasets, summarizes results, and assists in writing academic papers.
Objective: This study investigates the role of AI in the process of conducting a systematic literature review (SLR), focusing on its contributions and limitations at three key stages of its development, study selection, data extraction, and study composition, using glaucoma-related SLRs as case studies and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-based SLRs as benchmarks.
Methods: Four AI platforms were tested on their ability to reproduce four PRISMA-based, glaucoma-related SLRs.
Expert Opin Drug Discov
September 2025
1st University Department of Ophthalmology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Introduction: In silico trials represent an unprecedented opportunity for ocular drug development. These trials not only promise significant reductions in costs and development timelines but also meaningful improvements in both patient safety and compliance.
Areas Covered: This critical perspective gives discussion to the value of in silico trials for novel ocular drug discovery and development.